David B. Rawlins
Roseman University of Health Sciences(US)
Publications by Year
Research Areas
Cancer Treatment and Pharmacology, Diabetes Treatment and Management, Microtubule and mitosis dynamics, Cancer-related Molecular Pathways, Pancreatic function and diabetes
Most-Cited Works
- → N-(Cycloalkylamino)acyl-2-aminothiazole Inhibitors of Cyclin-Dependent Kinase 2. N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a Highly Efficacious and Selective Antitumor Agent(2004)251 cited
- → LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled Trial(2012)237 cited
- → The Pinene Path to Taxanes. 5. Stereocontrolled Synthesis of a Versatile Taxane Precursor(1997)172 cited
- → Discovery of Aminothiazole Inhibitors of Cyclin-Dependent Kinase 2: Synthesis, X-ray Crystallographic Analysis, and Biological Activities(2002)157 cited
- → Novel Class of LIM-Kinase 2 Inhibitors for the Treatment of Ocular Hypertension and Associated Glaucoma(2009)77 cited
- → Novel l-Xylose Derivatives as Selective Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes(2009)76 cited
- → 1H-Pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinases: highly potent 2,6-Difluorophenacyl analogues(2003)69 cited
- → Discovery of a Type III Inhibitor of LIM Kinase 2 That Binds in a DFG-Out Conformation(2014)66 cited
- → Discovery of LX2761, a Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitor Restricted to the Intestinal Lumen, for the Treatment of Diabetes(2017)64 cited
- → 1H-Pyrazolo[3,4-b]pyridine Inhibitors of Cyclin-Dependent Kinases(2003)63 cited